Aethlon Medical

Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI. The Aethlon segment is involved in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in 1991 and is headquartered in San Diego, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Aethlon Medical Advances Hemopurifier, Eyes Clinical Trials

Aethlon Medical is poised for pivotal clinical trials in Australia, focusing on its Hemopurifier technology's application in cancer treatment. Financially, the company has maintained a stable cash flow, managing a modest increase in expenses. The upcoming trials and potential expansion into the organ transplant sector highlight promising growth areas.

Aethlon Medical reports financial progress and global trial expansions

Aethlon Medical's Q1 2025 earnings call highlighted financial improvements, progress in Hemopurifier research, and global clinical trial expansions.
While challenges like expense projections and trial paperwork exist, opportunities in therapy enhancement and market expansion are promising for Aethlon.
The company's commitment to innovation, financial efficiency, and stakeholder communication bodes well for its future growth and success.
Investors can find confidence in Aethlon's strategic focus on advancing therapies and expanding its global reach in the oncology space.

Aethlon Medical reports strong Q2 performance amidst oncology trial progress

Aethlon Medical's Q2 2025 performance showcased financial stability, progress in oncology trials, and strategic cost reductions.
While challenges like trial complexities and data management exist, the company's strengths in innovation and transparency offer growth opportunities.
Navigating operational challenges and leveraging trial successes can drive Aethlon's long-term success in the healthcare industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Aethlon Medical exploded as much as 465% to a two-year high on Wednesday despite not releasing any news since last week, when one of its devices showed positive results in two COVID-19 patients. A June 8 report from Zacks Investment Research appeared spark conversation on Reddit, the social-networking platform largely responsible for many of the recent price swings in so-called meme stocks like GameStop and AMC Entertainment.

Aethlon Medical stock explodes 465% on heavy volume as new report about COVID-19 treatment inspires social-media discussion (AEMD)

Shares of AEMD stock are taking off on Wednesday following the firm's June 3 report of its coronavirus treatment returning promising results. The post AEMD Stock: The Historic Covid-19 News Sending Aethlon Medical Rocketing 350%+ appeared first on InvestorPlace.

AEMD Stock: The Historic Covid-19 News Sending Aethlon Medical Rocketing 350%+

Shares of Aethlon Medical Inc. skyrocketed more than fourfold on massive volume toward a two-year high in morning trading Wednesday, even though the California-based therapeutic technology company hasn't released any news in nearly a week. On June 3, the company pointed out a "pre-print manuscript" that has not yet completed peer review that was published in "Research Square," highlighting case studies of two critically ill COVID-19 patients who were given access to the company's Hemopurifier through Emergency Use.

Aethlon Medical stock more than quadruples on heavy volume

The stock price of Aethlon Medical, Inc. (NASDAQ: AEMD) increased by over 290% pre-market today. This is why it happened.

AEMD Stock Price: Over 290% Increase Pre-Market Explanation

Aethlon Medical Inc (NASDAQ: AEMD) stock surged probably in reaction to Zacks Article 'AEMD: First Ever In Vivo Removal Of COVID Virus From Bloodstream Of An Infected Patient.' The company recently announced the positive results from using its Hemopurifier in treating two critically ill COVID-19 patients, which is available under the FDA emergency use authorization (EUA).

Why Aethlon Medical Stock Skyrocketing?

SAN DIEGO, June 3, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced the publication of a pre-print manuscript highlighting two case studies of critically ill COVID-19 patients treated with the Aethlon Hemopurifier®. Both patients were given access to Hemopurifier® treatment through Emergency Use.

Aethlon Medical Publishes Case Studies of Two Critically Ill COVID-19 Patients Treated with the Hemopurifier®

SAN DIEGO, March 1, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that the company will participate in the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021,...

Aethlon Medical to Participate in Two Upcoming Healthcare Investor Conferences

Aethlon Medical, Inc. (AEMD) CEO Dr. Chuck Fisher on Q3 2021 Results - Earnings Call Transcript

SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its third quarter fiscal year 2021, ended December 31, 2020, at 4:15 p.m. EST...

Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 10, 2021

SAN DIEGO, Jan. 6, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced the expansion of its executive team with two key appointments: Guy...

Aethlon Medical Expands Leadership Team with Appointment of Chief Business Officer and Chief Medical Officer

SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced that the company will participate in the virtual H.C. Wainwright...

Aethlon Medical to Present at the H.C. Wainwright BioConnect 2021 Conference

Aethlon Medical (AEMD) news for Wednesday concerning the progress in an EFS for one of its medical devices has AEMD stock soaring higher. The post Aethlon Medical News Alert: Why AEMD Stock Is Rocketing Higher Today appeared first on InvestorPlace.

Aethlon Medical News Alert: Why AEMD Stock Is Rocketing Higher Today

SAN DIEGO, Nov. 3, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, announced today the appointment of Charles J. Fisher, Jr., M.D., as Chief Executive Officer,...

Aethlon Announces Appointment of Charles J. Fisher, Jr., M.D.

Aethlon Medical, Inc. (AEMD) CEO Tim Rodell on Q2 2021 Results - Earnings Call Transcript

SAN DIEGO, Oct. 19, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its second quarter fiscal year 2021, ended September 30, 2020, at 4:15 pm...

Aethlon Medical To Release Second Quarter Financial Results and Host Conference Call on October 28, 2020

SAN DIEGO, Aug. 27, 2020 /PRNewswire/ -- Aethlon Medical, Inc.

Aethlon Medical to Present at the LD Micro 500 Virtual Conference

Aethlon Medical, Inc. (AEMD) CEO Timothy Rodell on Q1 2021 Results - Earnings Call Transcript

SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Aethlon Medical, Inc.

Aethlon Medical To Release First Quarter Financial Results and Host Conference Call on August 11, 2020

Aethlon Medical, Inc. (AEMD) CEO Timothy Rodell on Q4 2020 Results - Earnings Call Transcript

SAN DIEGO, June 25, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its fiscal year ended March 31, 2020 and...

Aethlon Medical Announces Fiscal Year Financial Results and Provides Corporate Update

SAN DIEGO, June 18, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the U.S. Food and Drug Administration (FDA) has approved a...

Aethlon Announces FDA Approval of IDE Supplement  for COVID-19 Patients

Aethlon Medical, Inc. (AEMD) CEO Tim Rodell on Q3 2020 Results - Earnings Call Transcript

Inovio Pharmaceuticals

NanoViricides

Novavax

The story that has dominated this past week is that China is facing an outbreak of the coronavirus, and more countries around the world are seeing cases pop up.

Biotech Stocks Seeing the Biggest Boost From Coronavirus Outbreak

Sarepta Therapeutics

China is facing an outbreak of the coronavirus, and more countries around the world are seeing cases pop up.

Coronavirus Infections Climb Hand in Hand With These Biotech Stocks

Alpha Pro Tech

AstraZeneca

BioCryst Pharmaceuticals

Cleveland BioLabs

Cerus

Co-Diagnostics

Lakeland Industries

Moderna

Vir Biotechnology

Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter.

News for Aethlon Medical Stock (AEMD)